Peptide Injection Sites Compared: Subcutaneous vs Intramuscular vs Intranasal | Peptadex

Why Route of Administration Matters for Peptides

Peptides are protein fragments. When taken orally, most are degraded by stomach acid and digestive enzymes before they can be absorbed — which is why the majority of therapeutic peptides are administered by injection. The exceptions exist for specific reasons: small-molecule mimetics that bypass peptide bonds, specialized formulations that protect the peptide through the GI tract, or peptides with intrinsic properties that allow alternative routes like intranasal or sublingual.

Choosing the right route is not about preference — it is about whether the peptide will reach systemic circulation in active form. Each peptide has been studied (or used) at specific routes, and deviating from those routes typically reduces or eliminates efficacy.

Key Takeaways

• Subcutaneous injection is the most common route for peptide research and clinical use
• Intramuscular delivery offers faster absorption but is rarely required for peptide therapy
• Intranasal delivery works only for specific small peptides like Semax and Selank
• Oral peptides require either small-molecule design (orforglipron) or specialized absorption enhancers (Rybelsus)
• Site rotation prevents lipohypertrophy and injection-site reactions across all injection routes

Subcutaneous (Subq) Injection

Subcutaneous injection delivers the peptide into the fatty tissue layer just under the skin, above the muscle. Absorption is slower than intramuscular delivery, which produces a sustained, predictable plasma concentration profile that suits most peptide pharmacokinetics.

Common Subq Sites

• Abdomen: Two inches away from the navel in any direction. Most consistent absorption profile. Preferred for GLP-1 receptor agonists and most peptide research protocols.
• Outer thigh: The upper-outer quadrant. Consistent absorption, easy to self-administer.
• Back of upper arm: Requires assistance for self-injection. Less commonly used.
• Love handles / flanks: Acceptable alternative for site rotation.

Peptides Typically Given Subq

• Semaglutide (Ozempic, Wegovy)
• Tirzepatide (Mounjaro, Zepbound)
• Retatrutide (investigational)
• Ipamorelin
• CJC-1295
• Sermorelin
• Tesamorelin
• BPC-157 (in research protocols)

Technique Essentials

Use an insulin syringe (typically 29–31 gauge, 1/2-inch needle). Pinch the skin to lift fat away from muscle, insert at 90 degrees, inject slowly, then withdraw. Rotate sites to prevent lipohypertrophy — the localized fat tissue thickening that can develop with repeated injection at the same spot. Lipohypertrophy can also reduce absorption consistency, which is particularly relevant for GLP-1 dosing.

Intramuscular (IM) Injection

Intramuscular injection delivers peptide directly into muscle tissue, producing faster absorption than subcutaneous injection. For most peptides this is unnecessary — the slower subq absorption profile is preferred — but it is used for specific compounds and contexts.

Common IM Sites

• Deltoid: Upper outer arm, easy access
• Vastus lateralis: Outer thigh, large muscle
• Ventrogluteal: Hip muscle, requires anatomic landmarking

When IM Is Used

IM is the standard route for some research peptide protocols (occasionally for TB-500) and for peptide hormones requiring rapid absorption. It is also the route for many vaccine and large-volume injectable medications. For peptide therapy specifically, IM is the exception, not the rule.

Technique Essentials

Longer needle (1 to 1.5 inches, typically 22–25 gauge) to reach muscle. Insert at 90 degrees with the muscle relaxed. Slower injection of larger volumes than subq.

Intranasal Delivery

Intranasal administration delivers peptide through the nasal mucosa, allowing partial bypass of first-pass hepatic metabolism. It works only for small peptides with mucosal permeability — most peptides cannot be effectively absorbed this route.

Peptides Used Intranasally

• Semax — designed and studied as intranasal in Russian clinical research
• Selank — same context as Semax
• Oxytocin — intranasal preparations widely used in research and some clinical contexts
• PT-141 (Bremelanotide) — earlier formulations were intranasal; current FDA-approved Vyleesi is subcutaneous

Bioavailability via the nasal route varies widely. Even peptides designed for intranasal use achieve only 10–30% bioavailability compared to direct injection. Dose adjustments must account for this.

Oral Administration

Oral peptide delivery has historically been the holy grail and the largest barrier in peptide therapeutics. Two approaches have produced FDA-approved oral peptide-class products:

Specialized Absorption Enhancers

Rybelsus (oral semaglutide) uses SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) to transiently increase gastric absorption of intact peptide. Even with SNAC, bioavailability is approximately 1%, which is why Rybelsus requires fasting protocols and 4-ounce water restrictions.

Small-Molecule Mimetics

The newer approach replaces the peptide entirely with a small molecule that activates the same receptor. Foundayo (orforglipron), FDA-approved April 1, 2026, is the first small-molecule GLP-1 receptor agonist with no food or water restrictions. Bioavailability is sufficient that no special formulation is required.

For the broader oral GLP-1 landscape, see oral GLP-1 drugs in 2026.

Topical Application

Cosmetic peptides — Argireline, Matrixyl, copper peptide complex, and others — are formulated for topical application. Penetration depth into the dermis varies by peptide size and formulation. Topical bioavailability is generally low compared to injection but is the appropriate route for peptides whose target is the skin itself.

Site Rotation: Why It Matters

Repeated injection at the same spot causes:

• Lipohypertrophy: Fat tissue thickening, reduces absorption consistency
• Lipoatrophy: Fat tissue loss, less common but can be cosmetically significant
• Local inflammation: Redness, induration, and tenderness
• Variable absorption: Particularly problematic for narrow-therapeutic-index peptides

A simple rotation strategy: number 8–12 sites across abdomen and thighs, rotate through them in sequence, never inject the same site twice within 1–2 weeks.

Practical Decision Tree

• Is the peptide FDA-approved with an indicated route? Use the labeled route.
• Is the peptide studied predominantly via one route in research? Use that route.
• Has someone designed a specialized formulation (oral, intranasal)? Use only the formulation, not improvised conversions.
• For cosmetic peptides: Topical formulations as designed.

For technique fundamentals, see the peptide reconstitution guide. For storage between injections, see how to store peptides properly.

Disclaimer: This article describes administration routes used in clinical practice and research. It is not medical advice. Many peptides discussed are not FDA-approved for human use. Always consult a qualified physician before starting any peptide therapy and follow the prescribing label or research protocol for the specific compound.